BMS to ask FDA to sell Pravachol without a prescription

Share this article:
Bristol-Myers Squibb said it will ask the FDA to approve the sale of Pravachol without a prescription in its bid to become first to sell an over the counter cholesterol lowering drug in the U.S.
Currently Pravachol has sales of around $2.5 billion a year, but those numbers are expected to sharply drop once the drug loses patent exclusivity in 2006 and cheaper generics enter the market.
In recent years, the FDA has turned down similar requests to sell other statin drugs without a prescription arguing that self-diagnosis of high cholesterol is difficult and that it remains unclear whether low dose OTC versions of the drugs would produce health benefits.
Those attitudes may be changing, however, after Britain approved Merck's Zocor for sale without a prescription in that country, earlier this year and worldwide regulators come under pressure to make more medicines available over the counter to fight against runaway healthcare costs.
BMS also said that it has entered into an agreement with Bayer HealthCare for Bayer's Consumer Care Division to handle OTC sales and marketing for Pravachol in the United States, should the FDA approve OTC use of the drug. BMS said Bayer was selected given its experience in the cardiovascular category and the position it has achieved in the marketing of the Bayer Aspirin brand.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...